MX2022006146A - Metodos y composiciones para la neuroproteccion. - Google Patents
Metodos y composiciones para la neuroproteccion.Info
- Publication number
- MX2022006146A MX2022006146A MX2022006146A MX2022006146A MX2022006146A MX 2022006146 A MX2022006146 A MX 2022006146A MX 2022006146 A MX2022006146 A MX 2022006146A MX 2022006146 A MX2022006146 A MX 2022006146A MX 2022006146 A MX2022006146 A MX 2022006146A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- neuroprotection
- diseases associated
- neurodegenerative diseases
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000004112 neuroprotection Effects 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 abstract 4
- 101000685982 Homo sapiens NAD(+) hydrolase SARM1 Proteins 0.000 abstract 2
- 102100023356 NAD(+) hydrolase SARM1 Human genes 0.000 abstract 2
- 230000003376 axonal effect Effects 0.000 abstract 2
- 230000007850 degeneration Effects 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 1
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/02—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2)
- C12Y302/02006—NAD(P)+ nucleosidase (3.2.2.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/316—Phosphonothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
La presente invención se refiere a composiciones y métodos para tratar la neurodegeneración y las enfermedades neurodegenerativas asociadas con la degeneración axonal. La neurodegeneración y las enfermedades neurodegenerativas asociadas con la degeneración axonal se tratan con terapias que comprenden inhibidores de SARM1 tales como oligonucleótidos antisentido de SARM1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962940437P | 2019-11-26 | 2019-11-26 | |
PCT/US2020/062289 WO2021108602A1 (en) | 2019-11-26 | 2020-11-25 | Methods and compositions for neuroprotection |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022006146A true MX2022006146A (es) | 2022-10-18 |
Family
ID=74046136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022006146A MX2022006146A (es) | 2019-11-26 | 2020-11-25 | Metodos y composiciones para la neuroproteccion. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230242909A1 (es) |
EP (1) | EP4065714A1 (es) |
JP (2) | JP7528212B2 (es) |
KR (1) | KR20220119366A (es) |
CN (1) | CN115176002A (es) |
AU (1) | AU2020391206A1 (es) |
BR (1) | BR112022009772A2 (es) |
CA (1) | CA3159374A1 (es) |
IL (1) | IL293123A (es) |
MX (1) | MX2022006146A (es) |
TW (1) | TW202134436A (es) |
WO (1) | WO2021108602A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023177972A1 (en) | 2022-03-14 | 2023-09-21 | Eli Lilly And Company | Sarm1 rna interference agents |
TW202412817A (zh) * | 2022-07-21 | 2024-04-01 | 美商艾米利克斯製藥公司 | 寡核苷酸組合物及其方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040096830A1 (en) * | 2002-11-16 | 2004-05-20 | Isis Pharmaceuticals Inc. | Modulation of protein kinase D2 expression |
WO2012178022A2 (en) | 2011-06-24 | 2012-12-27 | University Of Massachusetts | Therapeutic applications targeting sarm1 |
US10968426B2 (en) * | 2015-05-08 | 2021-04-06 | President And Fellows Of Harvard College | Universal donor stem cells and related methods |
WO2017164230A1 (ja) | 2016-03-23 | 2017-09-28 | 国立大学法人 岡山大学 | リン酸化sarm1、抗体、sarm1リン酸化阻害剤、神経変性疾患の予防又は治療薬、スクリーニング方法、sarm1改変体及び使用 |
JP7548696B2 (ja) * | 2016-07-06 | 2024-09-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛関連障害を処置するための物質及び方法 |
CN110545804A (zh) | 2016-09-24 | 2019-12-06 | 华盛顿大学 | Sarm1 nad酶活性抑制剂及其用途 |
US20190365929A1 (en) * | 2017-02-22 | 2019-12-05 | Crispr Therapeutics Ag | Materials and methods for treatment of dystrophic epidermolysis bullosa (deb) and other collagen type vii alpha 1 chain (col7a1) gene related conditions or disorders |
AU2018351053A1 (en) | 2017-10-18 | 2020-05-07 | Washington University | Dominant negative sarm1 molecules as a therapeutic strategy for neurodegenerative diseases or disorders |
JP7478142B2 (ja) | 2018-06-07 | 2024-05-02 | ディスアーム セラピューティクス, インコーポレイテッド | Sarm1阻害剤 |
MA52812A (fr) | 2018-06-07 | 2021-04-14 | Disarm Therapeutics Inc | Inhibiteurs de sarm1 |
JP2021527125A (ja) | 2018-06-07 | 2021-10-11 | ディサーム・セラピューティクス・インコーポレイテッドDisarm Therapeutics, Inc. | Sarm1阻害剤 |
-
2020
- 2020-11-25 US US17/778,567 patent/US20230242909A1/en active Pending
- 2020-11-25 CN CN202080082124.2A patent/CN115176002A/zh active Pending
- 2020-11-25 KR KR1020227017020A patent/KR20220119366A/ko not_active Application Discontinuation
- 2020-11-25 EP EP20829411.6A patent/EP4065714A1/en active Pending
- 2020-11-25 MX MX2022006146A patent/MX2022006146A/es unknown
- 2020-11-25 CA CA3159374A patent/CA3159374A1/en active Pending
- 2020-11-25 WO PCT/US2020/062289 patent/WO2021108602A1/en active Application Filing
- 2020-11-25 JP JP2022530807A patent/JP7528212B2/ja active Active
- 2020-11-25 IL IL293123A patent/IL293123A/en unknown
- 2020-11-25 AU AU2020391206A patent/AU2020391206A1/en active Pending
- 2020-11-25 TW TW109141403A patent/TW202134436A/zh unknown
- 2020-11-25 BR BR112022009772A patent/BR112022009772A2/pt unknown
-
2024
- 2024-05-08 JP JP2024075968A patent/JP2024112834A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112022009772A2 (pt) | 2022-08-16 |
US20230242909A1 (en) | 2023-08-03 |
AU2020391206A1 (en) | 2022-05-19 |
WO2021108602A1 (en) | 2021-06-03 |
EP4065714A1 (en) | 2022-10-05 |
IL293123A (en) | 2022-07-01 |
TW202134436A (zh) | 2021-09-16 |
JP2023503994A (ja) | 2023-02-01 |
CN115176002A (zh) | 2022-10-11 |
JP2024112834A (ja) | 2024-08-21 |
KR20220119366A (ko) | 2022-08-29 |
CA3159374A1 (en) | 2021-06-03 |
JP7528212B2 (ja) | 2024-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501065A1 (en) | Compounds and compositions useful for treating disorders related to ntrk | |
MX2022003891A (es) | Anticuerpos anti-muc16 y sus usos. | |
MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
IL288914A (en) | Preparations and methods for the treatment of cancer | |
IL286350A (en) | Preparations and methods for the treatment of cancer | |
PH12020550833A1 (en) | Rnai constructs for inhibiting pnpla3 expression | |
ZA202104870B (en) | Methods and compositions for treating cancer | |
MX2022006146A (es) | Metodos y composiciones para la neuroproteccion. | |
IL285886A (en) | Preparations and methods for the treatment of laminopathy | |
EP4025590A4 (en) | METHODS AND COMPOSITIONS FOR TREATING CANCER | |
IL287982A (en) | Preparations and methods for the treatment of cancer | |
EP3965896A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | |
WO2008092099A3 (en) | Compositions and methods for treating hematopoietic malignancies | |
EP4003351A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
MX359337B (es) | Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer. | |
IL286153A (en) | Methods and preparations for the treatment of cancer | |
IL285796A (en) | Methods and preparations for the treatment of cancer | |
WO2013066485A3 (en) | Compositions and methods for treatment of metastatic cancer | |
EP4077690A4 (en) | METHODS AND COMPOSITIONS FOR TREATING CANCER | |
EP3983014A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | |
EP3823593A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTISM | |
PH12018501045A1 (en) | Treatment of retinal degeneration using progenitor cells | |
IL285036A (en) | Methods and preparations for the treatment of cancer | |
EP3962896A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | |
EP3823626A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTISM |